Indian Immunologicals unveils Measles and Rubella vaccine for children biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Indian Immunologicals launches Measles and Rubella vaccine for children biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Hyderabad-based Indian Immunologicals Limited (IIL), a vaccine manufacturer has announced receipt of approval from Drugs Controller General of India (DCGI) and State Drug Control Administration for manufacture of Measles-Rubella (MR) Vaccine.
This is the outcome of the Indo-Vietnam partnership,
The MR vaccine of Indian Immunologicals is the outcome of Indo-Vietnam partnership, wherein IIL has partnered with Center for Research and Production of Vaccines and Biologicals, also called Polyvac in Vietnam
Imperilled Immunity — India's ailing Vaccine PSUs - The Hindu BusinessLine thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
With Bharat Bio missing deadlines, Covaxin supply shrouded in mystery thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Indian Immunologicals’ COVID vaccine likely next year Updated: Updated: Animal trials on its indigenous vaccine are underway, says the PSU Share Article Animal trials on its indigenous vaccine are underway, says the PSU Hyderabad-based Indian Immunologicals Limited (IIL), the public sector unit under the National Dairy Development Board (NDDB), has announced that it has been working on an indigenous vaccine for COVID-19 and this is expected to come out next year into the market. IIL Managing Director K. Anand Kumar said on Friday that the currently animal trials are underway and the vaccine is likely to be available for vaccinating the people after this was completed. Incidentally, this has been one of the public sector firms identified to collaborate with Bharat Biotech to enhance production of Covaxin and production of drug subtance for making the vaccine is to be produced from June 15 onwards.
How pandemic fatigue led India to squander a chance to beat Covid while it was down Delayed action on shoring up vaccines, and India’s return to pre-pandemic normal with a vengeance have been seen as signs of fatigue as well as a level of complacence. Abantika Ghosh 18 April, 2021 10:04 am IST Text Size: A+ New Delhi: On 13 April, 101 days after the first two Covid-19 vaccines were approved in India, the central government took a decision to waive the requirement of bridging trials in the country for vaccines approved in Europe, Japan, the US etc. What prompted its rigidity in December last year, when it refused to grant the same waiver to the Pfizer mRNA vaccine, is a mystery. Pfizer eventually withdrew its application and now wants its entry to be subject to certain conditions.